Free Trial

Celldex Therapeutics (CLDX) Competitors

Celldex Therapeutics logo
$21.33 +0.35 (+1.67%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$21.57 +0.24 (+1.13%)
As of 07/8/2025 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CLDX vs. ALKS, LGND, BCRX, FOLD, INVA, DVAX, MNKD, OPK, NVAX, and GERN

Should you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), and Geron (GERN). These companies are all part of the "biotechnology" industry.

Celldex Therapeutics vs. Its Competitors

Alkermes (NASDAQ:ALKS) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Alkermes presently has a consensus target price of $40.00, suggesting a potential upside of 36.15%. Celldex Therapeutics has a consensus target price of $50.11, suggesting a potential upside of 134.93%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83
Celldex Therapeutics
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.89

Alkermes has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Alkermes has a net margin of 23.30% compared to Celldex Therapeutics' net margin of -2,366.07%. Alkermes' return on equity of 27.52% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes23.30% 27.52% 17.98%
Celldex Therapeutics -2,366.07%-23.46%-22.35%

In the previous week, Alkermes had 10 more articles in the media than Celldex Therapeutics. MarketBeat recorded 11 mentions for Alkermes and 1 mentions for Celldex Therapeutics. Alkermes' average media sentiment score of 1.26 beat Celldex Therapeutics' score of 1.16 indicating that Alkermes is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celldex Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.56B3.11$367.07M$2.0914.06
Celldex Therapeutics$7.02M201.69-$157.86M-$2.70-7.90

95.2% of Alkermes shares are owned by institutional investors. 4.4% of Alkermes shares are owned by insiders. Comparatively, 4.4% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Alkermes beats Celldex Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Celldex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLDX vs. The Competition

MetricCelldex TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.39B$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.06%
P/E Ratio-7.9020.8027.0020.10
Price / Sales201.69286.27428.95120.24
Price / CashN/A41.1936.8257.86
Price / Book1.897.487.985.56
Net Income-$157.86M-$55.04M$3.16B$248.40M
7 Day Performance-3.53%2.44%2.39%4.67%
1 Month Performance2.99%1.90%2.18%6.64%
1 Year Performance-42.62%4.35%33.82%21.31%

Celldex Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLDX
Celldex Therapeutics
3.0661 of 5 stars
$21.33
+1.7%
$50.11
+134.9%
-41.3%$1.39B$7.02M-7.90150Positive News
ALKS
Alkermes
4.9308 of 5 stars
$28.61
-0.7%
$40.00
+39.8%
+20.6%$4.75B$1.56B13.691,800Positive News
LGND
Ligand Pharmaceuticals
4.7911 of 5 stars
$113.68
-0.4%
$146.14
+28.6%
+32.5%$2.20B$167.13M-15.9780
BCRX
BioCryst Pharmaceuticals
4.4578 of 5 stars
$8.96
-4.3%
$16.89
+88.5%
+36.9%$1.96B$450.71M-34.46530
FOLD
Amicus Therapeutics
3.6815 of 5 stars
$5.73
-3.4%
$16.22
+183.1%
-38.8%$1.83B$528.29M-63.66480
INVA
Innoviva
3.8628 of 5 stars
$20.09
+0.7%
$55.00
+173.8%
+16.0%$1.25B$358.71M-19.89100
DVAX
Dynavax Technologies
4.3584 of 5 stars
$9.92
+0.1%
$24.00
+141.9%
-5.3%$1.19B$277.25M-19.08350
MNKD
MannKind
2.5223 of 5 stars
$3.74
-0.5%
$10.33
+176.3%
-32.8%$1.14B$285.50M37.40400Negative News
OPK
OPKO Health
4.5361 of 5 stars
$1.32
flat
$2.75
+108.3%
+5.4%$1.05B$713.10M-18.852,997
NVAX
Novavax
4.4849 of 5 stars
$6.30
-1.1%
$17.00
+169.8%
-41.6%$1.03B$682.16M2.381,990
GERN
Geron
2.8464 of 5 stars
$1.41
-5.4%
$5.06
+259.0%
-69.3%$949.01M$76.99M-6.7170Gap Down

Related Companies and Tools


This page (NASDAQ:CLDX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners